Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05241535 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects
A Phase 1 study of Healthy Subjects, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 2
- Study locations
NCT05241535 is a Phase 1 study of Healthy Subjects that has completed, run by Tanabe Pharma America. The registered enrollment target is 29 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05241535, a Phase 1 study of Healthy Subjects, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the effect of a single oral dose of MT-7117 on the QT/QTc interval in healthy subjects.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MT-7117
- DRUG moxifloxacin
Study Locations (2)
Florida
- Daytona Beach Clinical Research Unit - Daytona Beach
Texas
- Dallas Clinical Research Unit - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2022-01-12 |
| Est. Completion | 2022-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05241535
The ClinicalTrials.gov registry entry for NCT05241535 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (77% lower). The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05241535 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05241535 about?
NCT05241535 is a clinical study titled "Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects". The purpose of this study is to evaluate the effect of a single oral dose of MT-7117 on the QT/QTc interval in healthy subjects.
What is the current status of trial NCT05241535?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2022-01-12. Estimated completion is 2022-02-27.
What conditions does trial NCT05241535 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT05241535?
The interventions under investigation include: Placebo (DRUG), MT-7117 (DRUG), moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT05241535?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05241535 being conducted?
This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.